AI assistant
Poly Medicure Ltd Interim / Quarterly Report 2021
60661_rns_2021-11-01_fccfea39-3bba-45c3-aa35-93120f0f5aa0.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Poly Medicure Limited
Regd. Office : 232-8, 3• Floor, Okhlo Industrial Estate, Phase-Ill. New Delhi· 110020 (INOIA) T: +91 · 11 -33550700, 47317000, F: +91-11 · 26321894, 26321839 E: info aJpolymed1cure.com W: polymedicure.com CIN: L40300DL1995PLC066923
Dr1te: 1 1 10\ ember, 2021
Scrip Code: -531768
The Manager, BSE Limited, Departrnent of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, ?>.1umbai- 400001.
Scrip Code:- POL YMED
The Manager National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1-Block-G Bandra Kurla Complex, Bandra(E), Mumbai-400051.
Subject Outcome of the Board Meeting of the Company
Ref: Comp Hance of Regulation 30 and 33 of SEBI {LODR) Regulations, 2015
Dear Sir/ ?>. la dam,
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 1st November, 2021, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses:
- a) Unaudited Financial Results (Standalone & Consolidated) for the Second quarter and half year ended on 30th September 2021.
- b) Allotted 19,775 Equity Shares of Rs. 5 each, pursuant to exercise of an option under Employee Stock Option Scheme, 2016.
- c) Other Routine Businesses.
Kindly take a note of the same for your further needful and oblige us.
Thanking You,
Yours Sincerely
For Poly Medicure Li · · -~
**Avinash Chandra Company Secretary**
**PHLYMED**
#### POLY MEDICURE LIMITED
#### Regd. Office: 232B, 3rd Floor. Okhla Industrial Estate Phase III. New Delhi - 110 020 Website: www.polymedicure.com, E-mail: [email protected], CIN: L40300DL1995PLC066923 STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021
(T in lacs except per share data) Standalone Consolidated Standalone Consolidated **Particulars Quarter Ended** Half Year Ended **Half Year Ended Quarter Ended Year Ended Year Ended** 30.09.2021 30.06.2021 30.09.2020 30.09.2021 30.09.2020 30.09.2021 30.06.2021 30.09.2021 30.09.2020 30.09.2020 31.03.2021 31.03.2021 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income (Audited) a Revenue from operations 21,193.21 20.297.25 5,084.66 19,022.90 41.490.46 22,336.82 21,193.96 19,962.54 17 000 14 74,738.24 78,646.96 b Other income 1,229.16 $1.023.22$ 362.04 2,252.38 $70704$ 1,225.92 1,027.47 2,253.39 670.16 323.46 1,928.82 1.841.50 Total income(A) 2 Expenses 22,422.37 21,320.47 19,384.94 43,742.84 35,791.70 23,562.74 22, 221.43 20,286.00 45,784.17 37,670.30 76,667.06 80,488.46 $\overline{a}$ Cost of materials consumed 8,752.67 7,678.33 6.344.76 11,235.10 12,400.11 16,431.00 9.391.12 8,119.25 6,864.42 17,510.37 24,628.28 26,695.18 b Purchases of stock-in-trade 336.65 149.80 84.52 486.45 171.96 336.65 149.80 84.52 486.45 171.96 308.32 308.32 c Changes in Inventories of finished goods, work-in-progress and stock-in- $(1.311.75)$ $(932.35)$ $(648.04)$ $(2, 244.10)$ $(260.06)$ $(1, 382.68)$ $(1.072.72)$ $(911.05)$ $(2, 455.40)$ $(692.55)$ $(223.53)$ $(780, 56)$ d Employee benefits expense 3,551.55 3,461.70 3,373.95 7,013.25 6,149.51 3,905.48 3,740.95 3,660.40 7,646.43 6.686.69 13.074.22 14, 175.70 e Research and development expenses 499.82 386.51 311.09 886.33 609.39 499.86 386.59 311.09 886.45 609.62 1.314.18 1,314.45 f Finance cost $\frac{302.23}{1,255.27}$ 3.09 $263.84$ 338.95 556.05 305.32 526.93 19.63 $\frac{319.32}{1.287.15}$ 277.22 791.17 851.18 q Depreciation and amortisation expense $1,143.75$ 1,318.76 $2.241.77$ 4,752.20 1.114.26 2.574.03 2.184.84 1.349.54 2.636.69 4.631.42 h Other expenses 4,318.61 4,155.96 4,152.51 8.474.57 7,278.97 4,499.65 $4,336.70$ <br>17,267.04 8.836.35 7,587.66<br>29,561.31 14,804.68 15.497.66 4.301.50 Total expenses(B) 17.469.40 16,457.45 14,996.89 33,926.85 27,896.64 18,619.25 15,731.85 35,886.29 59,328.74 $62,814.13$ 3 Profit from operations before exceptional items (A-B) 4,952.97 4,863.02 7,895.06 4,943.49 9,897.88 17,338.32 4,388.05 4,954.39 4,554.15 8,108.99 9,815.99 17,674.33 4 Exceptional Items $\overline{a}$ 5 Share of Profit of an associate $\frac{64.99}{5,019.38}$ 43.06 163.53 $\frac{112.76}{8,221.75}$ 331.07 98.54 6 Profit before tax 4,952.97 4,863.02 4,388.05 9,815.99 7,895.06 5,042.03 4,597.21 10,061.41 17,338.32 18,005.40 7 Tax expense 1,175.99 1,167.64 2,287.35 1,111.36 1,175.99 1.135.89 2,287.35 2,125.22 1,111.36 2,165.13 $4.410.71$ 4,441.52 b Deferred tax 107.19 84.03 $(71.37)$ 191.22 $(115.38)$ 107.19 84.03 $(71.37)$ 191.22 $(115.38)$ $(8.34)$ $(M.8)$ c Earlier Year Taxes $(15.22)$ $(15.22)$ Total Tax Expense 1,218.55<br>3,823.48 1,260.02<br>3,759.36 2,049.75<br>6,172.00 1,218.55 1,260.02 2,478.57 2.009.84 1.096.27 2.478.57 4,387.15 1,064.52 4,417.96 8 Profit after tax 3,734.42 3,603.00 3,323.53 7,337.42 5.885.22 3,500.94 7,582.84 12,951.17 13,587.44 9 Other Comprehensive Income<br>Items that will not be reclassified to profit or loss: Remeasurements of defined benefit obligations 16.90 15.44 $(1.46)$ 16.99 15.44 7.91 $(1.46)$ 16.90 16.99 7.91 11.9 13.98 Tax impacts on above $(4.28)$ $\frac{(1.99)}{5.92}$ $(3.52)$ 0.36 $(4.25)$ $(4.28)$ $(3.89)$ $(1.99)$ $0.36$ $(4.25)$ $(3.89)$ $(3.52)$ **Total Other Comprehensive Income** $(1.10)$ 12.65 12.71 11.55 $5.92$ $(1.10)$ 12.65 11.55 10.46 10.46 $\overline{10}$ Total comprehensive income (comprising profit after tax and 7,348.97 3.513.65 12.961.63 3,733,32 3.615.65 3.336.24 5,891.14 3,822.38 3,772.01 7,594,39 6.177.92 13,597.90 other comprehensive income after tax) 11 Net Profit attributable to: 3,823.48 3,759.36 3,500.94 7,582.84 6,172.00 13,587.44 $\overline{a}$ $\cdot$ $\overline{\phantom{a}}$ $\overline{a}$ Foulty holders of the parent $\overline{\phantom{a}}$ Non-controlling interests ÷ $\overline{\phantom{a}}$ $\sim$ $\sim$ -12 Other Comprehensive income attributable to: $(1.10)$ 12.65 12.71 11.55 5.92 10.46 τ . ÷ Fourty holders of the parent $\overline{\cdot}$ $\overline{\phantom{a}}$ τ τ. Non-controlling interests 13 Total comprehensive income attributable to: τ 3,822.38 3,772.01 3,513.65 7,594.39 6,177.92 13,597.90 τ τ Equity holders of the parent $\sim$ $\overline{a}$ τ ÷ $\sim$ Non-controlling interests $\sim$ 4,794.03 4,412.35 4,794.03 4,794.03 4,412.35 4,794.03 4,412.35 4794.03 4,794.03 4,794.03 4,412.35 14 Paid-up equity share capital (Face Value of ₹ 5 each) 4.794.03 IS Reserve excluding Revaluation Reserves as per balance sheet of previous 91,763.02 $\blacksquare$ $\ddot{\phantom{a}}$ $\sim$ $\overline{\phantom{a}}$ $\overline{\phantom{a}}$ $\sim$ 90,606.91 $\sim$ $\sim$ **Service** $\sim$ accounting year. Earnings per share $16$ (Quarterly not annualised) ; $\frac{15.25}{15.24}$ $7.65$ 6.67 3.99 3.92 3.97 $\frac{7.91}{7.90}$ $\frac{6.99}{6.99}$ $\frac{1453}{1453}$ $\frac{3.89}{3.89}$ $3.76$ $3.77$ Basic (?) $rac{0.07}{6.67}$ $3.98$ $\frac{3.92}{3.92}$ $\frac{37}{196}$ $3.75$ $3.76$ 7.64 Diluted $($ ₹ )
Munauche (SNEWDELH) **AIMIT**
Scanned with CamScanner
| | <b>Statement of Assets and Liabilities:</b> | <b>Standalone</b> | | (₹ in lacs)<br>Consolidated | | | |
|--------------------|-------------------------------------------------------------------------|------------------------------------|----------------------------------|------------------------------------|----------------------------------|--|--|
| <b>Particulars</b> | | As at<br>30.09.2021<br>(Unaudited) | As at<br>31.03.2021<br>(Audited) | As at<br>30.09.2021<br>(Unaudited) | As at<br>31.03.2021<br>(Audited) | | |
| <b>ASSETS</b> | | | | | | | |
| | 1 Non-current assets | | | | | | |
| | (a) Property plant and equipment | 37.766.94 | 36.723.76 | 38,435.23 | 37.410.71 | | |
| (b) | Capital work-in-progress | 2,010.30 | 1,474.29 | 2,010.77 | 1.474.46 | | |
| | (c) Right of Use Asset | 158.41 | 216.58 | 158.41 | 216.58 | | |
| | (d) Investment Properties<br>Goodwill on consolidation | 448.78 | 452.82 | 448.78 | 452.82 | | |
| (e) | (f) Intangible assets | | $\tilde{\phantom{a}}$ | 2,858.11 | 2,858.11 | | |
| | (g) Intangible assets under development | 1,522.14 | 1,556.17 | 1,598.07 | 1,636.24 | | |
| | (h) Financial Assets | 584.59 | 643.34 | 593.08 | 646.51 | | |
| | (i) Investment in subsidiaries/associates | | | | | | |
| | (ii) Other financial assets | 4,518.90<br>2,663.81 | 3,979.85 | 1,112.30 | 940.34 | | |
| | (i) Other non-current assets | | 5.348.07 | 2,663.81 | 5,348.07 | | |
| | Total non-current assets | 1,489.55 | 810.94 | 1,498.14 | 810.94 | | |
| | | 51,163.42 | 51,205.82 | 51,376.70 | 51,794.78 | | |
| $\overline{2}$ | <b>Current assets</b> | | | | | | |
| (a) | <b>Inventories</b> | 14,989.61 | 10,938.27 | 16.904.04 | | | |
| (b) | <b>Financial assets</b> | | | | 12,648.20 | | |
| | (i) Investments | 36,087.25 | 34,501.25 | 36.087.25 | 34,501.25 | | |
| | (ii) Trade receivables | 18,590.44 | 14,955.37 | 19.801.78 | 15,649.62 | | |
| | (iii) Cash and cash equivalents | 326.27 | 279.47 | 1,464.75 | 495.46 | | |
| | (iv) Bank Balances other than (iii) above | 2.833.76 | 2,460.87 | 2,833.76 | 2,460.87 | | |
| | (v) Loans | 34.96 | 33.30 | 34.96 | 33.30 | | |
| | (vi) Other financial assets | 304.39 | 330.24 | 389.92 | 416.74 | | |
| | (c) Other current assets | 4,360.39 | 4.036.60 | 4,685.11 | 4,372.83 | | |
| | <b>Total current assets</b> | 77,527.07 | 67,535.37 | 82,201.57 | 70,578.27 | | |
| | | | | | | | |
| | <b>TOTAL ASSETS</b> | 128,690.49 | 118,741.19 | 133,578.27 | 122,373.05 | | |
| | | | | | | | |
| | <b>EQUITY AND LIABILITIES</b> | | | | | | |
| | <b>EQUITY</b> | | | | | | |
| | (a) Equity share capital | 4,794.03 | 4.794.03 | 4,794.03 | 4,794.03 | | |
| | (b) Other equity | 95,595.76 | 90,606.91 | 96,983.48 | 91,763.02 | | |
| | <b>Total equity</b> | 100,389.79 | 95,400.94 | 101,777.51 | 96,557.05 | | |
| | | | | | | | |
| | <b>LIABILITIES</b> | | | | | | |
| 1 | <b>Non-current liabilities</b> | | | | | | |
| (a) | <b>Financial liabilities</b> | | | | | | |
| | (i) Borrowings | 4,537.21 | 5,973.95 | 5,274.07<br>91.86 | 6,327.71<br>196.63 | | |
| (b) | (ii) Lease Liabilities<br>(iii) Other financial liabilities | 91.86<br>71.10 | 196.63<br>87.56 | 71.10 | 87.56 | | |
| | Provisions | 281.20 | 230.98 | 382.75 | 326.73 | | |
| (c) | <b>Government Grants</b> | 355.18 | 347.29 | 383.92 | 433.26 | | |
| | (d) Deferred tax liabilities (Net) | 1,517.02 | 1.304.45 | 1,517.02 | 1,304.45 | | |
| | <b>Total non-current liabilities</b> | 6,853.57 | 8,140.86 | 7,720.72 | 8,676.34 | | |
| | | | | | | | |
| 3 | <b>Current liabilities</b> | | | | | | |
| | (a) Financial liabilities | | | | | | |
| | (i) Borrowings | 7,241.80 | 6,295.80 | 8,145.26 | 7,085.82 | | |
| | (ii) Lease Liabilities | 100.81 | 132.35 | 100.81 | 132.35 | | |
| | (iii) Trade payables | | | | | | |
| | a) total outstanding dues of micro enterprises and small enterprises | 1,016.12 | 1.047.72 | 1.016.12 | 1,047.72 | | |
| | b) total outstanding dues of creditors other than micro enterprises and | 7,126.65 | 4,562.54 | 8,422.40 | 5,404.29 | | |
| | small enterprises | | | | | | |
| | (iv)Other financial liabilities | 4.610.35 | 2,007.57 | 4,781.10 | 2,121.47 | | |
| (b) | Other current liabilities | 904.54 | 1,052.91 | 1,167.49 | 1.232.52 | | |
| (c) | <b>Provisions</b> | 32.16 | 44.27 | 32.16 | 44.27 | | |
| (d) | Current Tax Liabilities ( Net) | 414.70 | 56.23 | 414.70<br>24,080.04 | 71.22 | | |
| | <b>Total Current Liabilities</b> | 21,447.13 | 15,199.39 | | 17,139.66 | | |
| | TOTAL EQUITY AND LIARILITIES | 128.690.49 | 118.741.19 | 133.578.27 | 122,373.05 | | |
TRIMES PLUS CHEWDELHI
| Cash Flow Statement for the half year ended 30 September 2021 | <b>Standalone</b> | | (₹ in lacs)<br>Consolidated | | |
|-----------------------------------------------------------------------------|------------------------|---------------------------------------------------------------------------------|-----------------------------|-------------|--|
| <b>Particulars</b> | <b>Half Year ended</b> | | <b>Half Year ended</b> | | |
| | | 30 September 2021 30 September 2020 30 September 2021 30 September 2020 | | | |
| A CASH FLOWS FROM OPERATING ACTIVITIES | (Unaudited) | (Unaudited) | (Unaudited) | | |
| Profit before tax and exceptional items | | | | (Unaudited) | |
| <b>Adjusted for:</b> | 9,815.99 | 7,895.06 | 10,061.41 | | |
| Depreciation and amortisation | | | | 8,108.99 | |
| Share in Income from Associate | 2,574.03 | 2,184.84 | 2,636.69 | | |
| Interest expense | | | (163.53) | 2,241.77 | |
| Dividend Incorne/governing council share | 305.32 | 526.93 | 338.95 | 112.76 | |
| <b>Interest income</b> | | (47.55) | | 556.05 | |
| Loss/(profit) on sale of fixed assets, net | (131.86) | (168.26) | (132.47) | (4.69) | |
| Debts/advances written off | 5.46 | (2.11) | 5.46 | (168.99) | |
| | 1.74 | 14.05 | 1.74 | (2.11) | |
| Provision for doubtful debts and advances | | 13.01 | 2.14 | 14.05 | |
| Deferred employee compensation expenses (net) | 54.29 | 7.99 | 54.29 | 13.01 | |
| Unrealised foreign exchange (gain) /loss | (66.88) | 310.50 | | 7.99 | |
| <b>Other Comprehensive Income</b> | 15.44 | 7.91 | (66.88) | 310.50 | |
| Ind AS & Other adjustments | (1, 187.18) | (334.29) | 15.44 | 7.91 | |
| | | | (1, 183.35) | (361.97) | |
| Operating profit before working capital changes | 11,386.35 | 10,408.08 | | | |
| | | | 11,569.89 | 10,835.27 | |
| Movement in working capital | | | | | |
| Decrease/(increase) in inventories | (4,051.34) | | | | |
| Decrease/ (increase) in sundry debtors | (3,588.74) | 41.41 | (4.255.84) | (361.77) | |
| Decrease/(Increase) in financial assets | 29.83 | (252.16) | (4, 104.49) | (292.28) | |
| Decrease/(Increase) in other assets | | 113.53 | 58.69 | 87.11 | |
| Increase/ (decrease) in trade payables | (311.35) | 99.99 | (299.84) | 79.28 | |
| Increase/ (decrease) in other financial liabilities | 2,519.90 | 3.43 | 2,973.90 | 58.26 | |
| Increase/ (decrease) in other liabilities | 356.94 | 260.18 | 411.57 | 282.99 | |
| Increase/ (decrease) in provisions | (133.34) | (693.37) | (65.03) | (581.81) | |
| Cash generated from operations | 38.11<br>6.246.36 | 32.70 | 43.91 | 51.04 | |
| Direct taxes paid (net of refunds) | | 10,013.79 | 6,332.76 | 10,158.09 | |
| Net cash from operating activities (A) | (1,928.88) | (1,638.53) | (1,952.46) | (1,669.92) | |
| | 4,317.48 | 8,375.26 | 4,380.30 | 8,488.17 | |
| <b>B CASH FLOWS FROM INVESTING ACTIVITIES</b> | | | | | |
| Purchase of fixed assets (including capital advances) | | | | | |
| Purchase of Investments (net) | (4, 802.17) | (4, 434.21) | (4,948,08) | (4.413.68) | |
| Proceeds from / (Investment in) Fixed Deposits (net) | (1,042.05) | (1,767.63) | (503.00) | (1, 825.83) | |
| Proceeds from sale of fixed assets | 2.180.30 | 704.57 | 2,180.30 | 704.56 | |
| Dividend Income/governing council share | 1.12 | 41.30 | 1.12 | 41.30 | |
| Interest income | 27.89 | 19.48 | 27.89 | 19.48 | |
| Net cash used for investing activities (B) | 275.35 | 227.95 | 275.96 | 228.68 | |
| | (3,359.55) | (5, 208.54) | (2,965.81) | (5, 245.49) | |
| C CASH FLOWS FROM FINANCING ACTIVITIES | | | | | |
| Proceeds from (Repayment) of borrowings / deferred payment liabilities | (465.53) | (2,474.08) | 31.82 | (2,537,36) | |
| (net) | | | | | |
| Repayment of Lease Liabilities including interest | (146.19) | (57.00) | (146.19) | (57.00) | |
| Interest / Finance charges paid | (299.41) | (528.18) | (330.82) | (568.25) | |
| Net cash from/(used for) financing activities (C) | (911.13) | (3,059.26) | (445.19) | (3, 162.61) | |
| | | | | | |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | 46.80 | 107.46 | 969.30 | 80.07 | |
| Cash and cash equivalents at the beginning of the year | 279.47 | 189.46 | 495.46 | 485.74 | |
| Cash and cash equivalents at the end of the period | 326.27 | 296.92 | 1,464.75 | 565.81 | |
| | | | | | |
| COMPONENTS OF CASH AND CASH EQUIVALENTS | | | | | |
| Balances with Banks in current account | 309.99 | 283.01 | 1,446.88 | 546.81 | |
| Cheques, drafts on hand | | | | | |
| Cash on hand (including foreign currency notes) | 16.28 | 13.91 | 17.87 | 19.00 | |
| Fixed deposits with banks, having original maturity of three months or lest | | | | | |
| Cash and cash equivalents at the end of the period | 326.27 | 296.92<br>under indirect method as set out in INO AS-7 "Statement of Cash Flow" | 1,464.75 | 565.81 | |
$O(C)$ Munarshl E NEW DELHI **VALT**
**Notes:**
- I The above Unaudited st.indalone and c.onsolidated results were reviewed and ecommended . company. r by the Audit Coomittee & approved by the Board of Directors at their respective meetings held on 01st November, 2021 and have also been limited reviewed by Statutory auditors of the
- 2 Tlle st.indalone and c.onsolldated financlal results have been prepared In ac.co,da Ith th •nc1n1- 1es Act, 2013. nee w e pn ~ and procedures or Indian Acmunting Standards ("Ind AS") as notirted under the Companies {lndldn AccounUng Standards) Rules, 2015 as specified In SccUon Ill of the Compan
- 3 The Consolidated unaudited Flnanc:Jal Results of the Company and its Foreign Subsldlarles/lndlan subsidiary ("Group") and associate have been prepared as per IND AS 110 "Consolidated An,mclal statements• and IND AS 28 on "Investment In Assodates·. The following entitles have been com,ldered In Consohdaled quarterly financ:Jal results.
- I. Poly Medlcure (Lalyang) Co. ltd Wholly owned Subsidiary (Management certified)
- 2. Poly Medicure B V NeU,erlands(Consolldaled) Wholly owned Subsidiary (Management certified)
- J. Ptiln I health India Pvt Ltd.· Wholly owned Subsidiary (Limited reviewed)
- 4. Ultra for Medical Products Co.(UMIQ Egypt- Associate (Management certJfied)
◄ In line with the provisions of Ind AS 108- O~raUng Segments and on U1e basis or review of operations belng done by the mJnagement or the Company, the operations of the g,oop falls under medical devices, which Is considered to **be** the only reportable segment by Uie managemenl
S TIM? Company continues lo monitor the Impact of COVID 19 on Its busslness Including Its Impact on customers, supply chain etc. Due care has been exercised In c:ondudlng on slgnlflcant accounting Judgement and estimates Including In relation to rea,verablllty of ~bles, Inventory and other financial assets based on lnfonnatlon available to date while preparing the Company's financial results as or and for the quarter and half year ended JO September 2021.
6 During the quarter ended 30th September 2021, a rH?W Company Polyhealth Medical Inc. In USA was Incorporated which Is wholly owned subsldldry of *Poly* Medlcure B V • Netherlands, accordingly Polyhealth Medical Inc. have become step subsidiary of the company.
7 During the quarter ended 31st March, 2021, the company had Issued 76,33,587 equity shares of Rs 5/· each at premium of Rs. 519/· each (Issue Price per share Rs. 52◄/· each) amounting to Rs 0,000 lacs to Qualified lnstltutional Investors on QIP basis.The proceeds of.QIP **have** been utlllzed as per details given below as on JO September 2021:
| S.No | Particulars | Amount<br>ta. In•-• |
|------|------------------------------------------------------------------------------------------|---------------------|
| I | 1"'11> dun> I=""<br>-<br>I 1":CT nr De In< SQ L>r <l<br>I</l<br> | 700 nc |
| 2 | f,,,. •"" ~<br>ina "'"""I limits<br>R | '- ,,n a/ |
| J | Investment In subsidiary | 539.00 |
| 4 | (apltal experldib.Jre | 802.17 |
| 5 | Amount temporanly Invested in fi•ed deposits and liquid mutual funds pending utilisatlon | 27,676.9◄ |
| | T-••• | -.AAA |
a Previous period figures have been regrouped wherever necessary to conform to the current year dass,fication.
<sup>9</sup>The unaudited results of Poly Medicure Limited for the quarter and half year ended 30th September 2021 are available on our website, www.polymedicure.com and on the Stock Exchange website www.nsel
**Place** : **New Delhi Date** : Olst **November** 2021
\_...,. -
### **POLY MEDICURE LIMITED**
-------------------------------------
| | | | | | | (I in lacs except per share data) | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------|----------------------|----------------------|-----------------------------------|----------------------|--|
| | <b>Particulars</b> | <b>Standalone</b> | | | Consolidated | | | |
| | | <b>Quarter Ended</b> | <b>Half Year Ended</b> | <b>Quarter Ended</b> | <b>Quarter Ended</b> | <b>Half Year Ended</b> | <b>Quarter Ended</b> | |
| | | 30.09.2021 | 30.09.2021 | 30.09.2020 | 30.09.2021 | 30.09.2021 | 30.09.2020 | |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |
| | Total Income from operations | 22,422.37 | 43,742.84 | 19,384.94 | 23,562.74 | 45,784.17 | 20,286.00 | |
| | Net Profit/(Loss) for the period (before Tax, Exceptional and/or | | | | | | | |
| | Extraordinary items) | 4,952.97 | 9,815.99 | 4,388.05 | 5,042.03 | 10,061.41 | 4,597.21 | |
| | Net Profit/(Loss) for the period before Tax | | | | | | | |
| | (after Exceptional and/or Extraordinary items). | 4,952.97 | 9,815.99 | 4,388.05 | 5,042.03 | 10,061.41 | 4,597.21 | |
| | Net Profit/(Loss) for the period after Tax | | | | | | | |
| | (after Exceptional and/or Extraordinary items) | 3,734.42 | 7,337.42 | 3,323.53 | 3,823.48 | 7,582.84 | 3,500.94 | |
| | Total Comprehensive Income for the period [Comprising Profit/(Loss) for<br>the period (after tax) and Other Comprehensive Income (after tax)] | 3,733.32 | 7.348.97 | 3,336.24 | 3,822.38 | 7,594.39 | 3,513.65 | |
| | 6 Equity paid up share capital | 4,794.03 | 4,794.03 | 4,412.35 | 4,794.03 | 4,794.03 | 4,412.35 | |
| | Earnings per share (Face Value of ₹ 5 each) | | | | | | | |
| | (Quarterly not annualised): | | | | | | | |
| | Basic $(3)$ | 3.89 | 7.65 | 3.77 | 3.99 | 7.91 | 3.97 | |
| | Diluted (F) | 3.89 | 7.64 | 3.76 | 3.98 | 7.90 | 3.96 | |
1 The above unaudited standalone and consolidated financial results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 01 November 2021 and have a
2015/he above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30,2021 filed with the Stock Exchanges under Regulation 33 of the full formulat of the unaudited Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com. Wurd
**Place: New Delhi**
Date: 01st November 2021
**Managing Directo**
CU а 2 **NEW DEL**
# *?vt C <Bliandari el Co.*
*Cfiarterecf }lccountants*
*204, Secoruf 'Ffoor, ~t,111islia cJJuiGfi11g, 75-16, :Nefi.ru. Pface, :New (J)effzi-110019 ((J)effzi) ~o6i{e: 9810236616, 'E-mai{: mc6codc{lii@gmai[com*
**Independent Auditors' Review Report on the Quarterly and year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements} Regulations, 2015 as amended**
**To Board of Directors** Poly Medicure Limited 232-8, lllrd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi- 110020
We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medi cure Limited ("the company"} for the quarter and half year ended 30th Sept 2021 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 oft he SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review oflnterim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated S'h July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.
For M C Bhandari & Co. Chartered Accountants Finn Registration No. 3030
~ Ravindra Bhandari
**Partner** Membership No. 097466 **UDIN:~/'9-?~~~~~~~**
Place of signature: New Delhi Date:Ol <sup>11</sup> Nov. 2021.
# :Jvt *C <Bhandari* e1 *Co.*
*C{zarterea }lccountants*
20-l, Secomf<ffoor, 5lt.111isfia <JJuiufi11g, 75-76, '}[efiru <P{ac.e, *'}few* <Deffii-110019 (<Deffii) ~Ho6i{e : 9810236616, <E-mai{: m~6coacClii@gmai[com
**lndepemlcnt Auditors' Review Report on the Quarterly and year to date Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board oflndia (Listing Obligations and Disclosure Requirements} Regulations, 2015 as amended**
**To Board of Directors** Poly Medicure Limited 232-B, lllrd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi- 110020
- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Poly Medicure Limited (" Parent"} and its subsidiaries (the parent and its subsidiaries together referred to as 'the group') and its share of the profit after tax of its associate for the quarter and half year ended 30th Sept 2021 (the "Statement"} attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements} Regulations 20 IS as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMDl/44/2019 dated March 29, 20l9('the Circular'}.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE} 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Regulation, to the extent applicable.
- 4. The Statement includes the results of the entities mentioned in Annexure I to the statement.
- *5.* We did not review the financial results of 2 foreign subsidiaries included in the consolidated unaudited financial results, whose financial results reflect total revenues of Rs.1262.61 lacs and Rs.2284.35 lacs, total net profit/ (loss) of Rs.(9.39) lacs and Rs.82.02 lacs, for the quarter and half year ended 30th Sept 2021, respectively as considered in the consolidated unaudited financial results.
The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs.98.5~ lacs ?nd Rs.163.53 la~s, for the quarter an~ half ye~r ended 30th Sept 202 ~~ec\!.\_vely as considered an the statement, m respect of one foreign associate, whose financial ~~~ Rv?ttot been reviewed by us. <.J · <sup>0</sup> ~ c;
Scanned with CamScanner
~ 11.
These financial results are certified by the management of respective companies and our conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the basis of financial statement as certified and procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of above matter.
- 6. ln respect of subsidiaries and associate located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and are management certified. The Parent's management has converted the financial results of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective country to the accounting principles generally accepted in India. We have reviewed conversion adjustment made by the parent's management. Our conclusion in so far as it relates to balances and affairs of such subsidiaries and associate located outside India is based on the conversion adjustments prepared by the management of the Parent and reviewed by us.
- 7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial statements as certified by the management referred to paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid in the aforesaid Indian Accounting Standard specified under Section 133 of Companies Act,2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with circular,. including the manner in which it is to be disclosed, or that it contains any material misstatement.
For M C Bhandari & Co. Chartered Accountants Firm's Registration numb
~ indra Bhandari
Partner Membership number: 097466
Place: New Delhi Date: 0P'Nov. 2021.
## Annexure I: List of entities consolidated as at Sept 30, 2021
- 1. Poly Medicure (Laiyang) Co. Ltd.- China Wholly owned Subsidiary.
- 2. Poly Medicure BV Netherlands (Consolidated) Wholly owned Subsidiary
- 3. Ultra for Medical Products Co. (UMIC) Egypt Associate
- 4. Plan 1 Health India Pvt. Ltd.
